600285.SH
羚锐制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 19.58
+0.20%Year over year
Reported trailing growth
- Revenue
- +9.6%
- EBITDA
- —
- EBIT
- +9.0%
- EPS
- +4.7%
- Free cash flow
- -21.9%
- Operating cash flow
- -25.7%
Forward estimates
Based on analyst estimates
- Revenue
- -73.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.7%
- EBITDA
- +18.4%
- EBIT
- +19.7%
- Net income
- +17.7%
- EPS
- +17.0%
- Free cash flow
- -14.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026